Solideon Announces $1.25 Million AFWERX Contract

BERKELEY, Calif.--(BUSINESS WIRE)--(Additive Space Technologies Inc., d.b.a. Solideon) announces it has been selected by AFWERX for a Direct-to-Phase II contract in the amount of $1.25 million focused on developing a single pallet additive manufacturing cell that is capable of flexibly manufacturing critical systems across expeditionary environments. to address the most pressing challenges in the Department of the Air Force (DAF). The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018, which expanded the range of innovations the DAF funded, and now, on May 21st, 2025, Additive Space Technologies Inc, d.b.a Solideon will start its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America.
Quote From Company
'The future of industrial power isn't centralized — it's deployable. This award is a signal that the Department of the Air Force is ready to break from the past and lead with agility. With this contract, we're building the foundation for a world where manufacturing happens not in factories but wherever the mission demands — from airbases to shipyards and, eventually, orbit.' CEO Oluseun Taiwo
The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense, or the U.S. government.
About Additive Space Technologies Inc., d.b.a. Solideon
Solideon is revolutionizing manufacturing by transforming readily available robotic arms into multi-robotic-enabled factories. This innovative approach empowers end-users with the capability to robotically weld, fabricate, and assemble entire structures on-site. By doing so, Solideon is fundamentally reshaping how the industrial base approaches the manufacturing of critical assets, such as ships, submarines, and other large vehicles.
About AFRL
The Air Force Research Laboratory is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development, and integration of affordable warfighting technologies for our air, space, and cyberspace forces. With a workforce of more than 12,500 across nine technology areas and 40 other operations across the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit afresearchlab.com.
About AFWERX
As the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 370 military, civilian and contractor personnel at four hubs and sites executing an annual $1.4 billion budget. Since 2019, AFWERX has awarded over 10,400 contracts worth more than $7.24 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit: afwerx.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Boston Globe

3 days ago

• Boston Globe

For Boston's budding biotechs, an uncertain future amid funding cuts

Early stage startups, operating without much financial cushion, are feeling the impact sooner than better-established companies. Advertisement Dépis, and many entrepreneurs like him, are looking for ways to get their science funded. For example, LabCentral, a biotech startup incubator, has a program that allows big pharmaceutical companies to invest in cutting-edge science without making long-term commitments. Pharma companies cover the costs of lab space for individual scientists for a year, providing an easy exit if the research doesn't prove promising. In its recent five-year strategic plan, the Massachusetts Biotechnology Council pitched the idea of a seed fund to support companies that graduate from the trade group's incubator program. Discussions are underway with MassBio's partners such as LabCentral and the Massachusetts Life Sciences Center, a quasi-public state agency. Advertisement 'What's happened this year just validated our plans,' said MassBio CEO Kendalle Burlin O'Connell. 'We knew that we needed to support these early stage companies. We really, really feel it's imperative for Massachusetts to be an entrepreneur, founder-centric ecosystem.' Dépis — who is researching techniques to better deliver drugs to treat immune diseases — says such support is sorely needed. Earlier this year, he applied for a federal Small Business Innovation Research grant; then the government employee responsible for his application was laid off. Two weeks later, the employee was reinstated, but Dépis's application remains in limbo. 'I'm in a position where time is critical,' Dépis said. 'For me that translates into a higher chance to not have the funding in time that I need to survive.' And Dépis is not alone. Before the post-COVID biotech slump, companies accepted at LabCentral could typically secure funding and move into the space in a few weeks. Now, startups are taking six months to a year to move in — if they move in at all, said LabCentral CEO Maggie O'Toole. Startups at LabCentral are staying longer, unable to raise the money needed to grow their companies and expand into their own facilities, O'Toole said. The average length of tenancy doubled to about 36 months from 18 months, Some startups, affected by the Trump administration's grant cuts, have had to give up their LabCentral benches because they can't pay the rent. 'It was nothing to do with the promise of their science,' O'Toole said. 'They had received [approval for] funding that never came through.' Advertisement Robert Coughlin, a managing director at the commercial real estate firm JLL and former MassBio CEO, said the biotech industry is going through a downturn reminiscent of the Great Recession of 2008. Layoffs have spread across the sector. Earlier this month, Boston-based Vertex Pharmaceuticals said it would Moderna, the Cambridge biotech that soared with the success of its COVID vaccine, has gone through recent layoffs. In 2024, employment across Massachusetts' life sciences sector stagnated for the first time in more than 10 years, according to a report from the Massachusetts Biotechnology Education Foundation. Boston's commercial real estate sector has been hurt by the biotech slump. The vacancy rate for lab space has reached 32 percent, the highest among major metropolitan areas, according to JLL's most recent US Life Sciences Property Report. While conditions seem dismal, Coughlin said, he noticed a sense of optimism at the BIO conference. The annual convention not only attracted big crowds from established biotech centers, but also representatives from states and countries looking to invest in and build their own life sciences sectors. 'People want to get together,' Coughlin said. 'They want to collaborate, they want to talk about these challenges.' Marin Wolf can be reached at

Yahoo

6 days ago

• Yahoo

Analysts revamp forecast for Nvidia-backed AI stock

Analysts revamp forecast for Nvidia-backed AI stock originally appeared on TheStreet. I have a virtual private server with several services running on it. It has replacements for Google Drive, Whatsapp, and Github (or Gitlab). Getting a sufficiently good internet connection that would allow me to use a real (on-premise) machine instead of a virtual one is very difficult where I live. I've been maintaining this server without any (serious) problems for a couple of years. However, in the past few months, the situation has changed, for the worse. Nothing brings me more joy than an occasional email from my VPS provider telling me that my server's CPU usage has been averaging at 98% for the last 2 hours. My server, which was almost invisible for a very long time, has become a target of scrapers and scanners.I am not alone in having this issue. Many prominent open-source projects had to protect themselves, too, and recently they started using "Anubis" for this. (Not the malware with the same name) Why the sudden change, you might ask? Well, an increasing number of companies think they will be the ones to create this 'incredible artificial intelligence.' So, they are scraping any website, regardless of whether its data is relevant and reliable. The more data they can collect, the better, seems to be the prevailing modus operandi. And once they're done collecting, throw everything into the blender and hope for the best. What if you are a little startup, with the aforementioned goals of writing incredible AI, and you've done the previous step of collecting the data, and now you just need that blender? Perhaps you have some investor money, but can't build that blender yourself. After all, Graphics cards used for AI training cost an arm and a leg. This is where CoreWeave () comes in. Just like the VPS providers that enable people like me who can't use real machines for their servers to use their servers instead, CoreWeave enables companies that can't afford AI servers to do their AI training on its GPU mega clusters. More AI Stocks: Wall Street veteran doubles down on Palantir Analysts double price target of new AI stock backed by Nvidia OpenAI teams up with legendary Apple exec Considering that the company's business model is 'renting' Nvidia () graphics cards, it is not surprising that the company has become Nvidia's largest holding, making up more than 78% of Nvidia's disclosed released its earnings report for Q1 2025 on May 14th. Here are the highlights: Revenue of $981.6 million, a 420% increase year-over-year. Net loss of $314.6 million, a 143% increase YoY. Adjusted EBITDA of $606.1 million, a 480% increase YoY. Guidance for the full year 2025 was: Revenue from $4.9 billion to $5.1 billion Capital expenditures of $20 billion to $23 billion Bank of America analysts, Brad Sills and Carly Liu, shared their opinions on the CoreWeave stock. "In our view, the AI infrastructure [capital expenditures] growth rate is peaking, though still very healthy (estimates are likely to move higher on a larger base), led by OpenAI. OpenAI's ChatGPT is the single largest consumer of AI workloads and is growing at a rapid pace. Therefore, we see solid sustained demand in CoreWeave's AI infrastructure market," said analysts In Q1, CoreWeave expanded its deal with OpenAI bringing the total contract value to $15.9 billion. The company also signed a new hyperscaler customer in Q1. It has also increased the average contract duration to four and a half years from four years since forecasted $21 billion of negative free cash flow for the company through calendar year 2027, driven by high capital expenditures. CoreWeave funds the majority of its capital expenditures with debt. The company managed to lower the interest rate in the recent debt raise of $2 billion to 9.3%, from 11% in calendar year 2024. "However, this remains a small % of the total incremental debt required from here, raising some questions, in our view," continued analysts. Sills and Liu noted that the stock is trading at twenty-five times its calendar year 2027 EBIT estimate, which is a premium to the peer group that is trading at sixteen times the estimate. They set the new price objective for CoreWeave, raising their target from $76 to $185, which is 29 times their calendar year 2027 EBIT estimate (vs. 16x previously), or 0.4 times adjusted for 69% growth. That said, they cut their rating on the stock after CoreWeave's recent rally, arguing there's less room for shares to head higher. "We believe much of the near-term upside has been priced in and downgrade our rating to neutral from buy," concluded revamp forecast for Nvidia-backed AI stock first appeared on TheStreet on Jun 16, 2025 This story was originally reported by TheStreet on Jun 16, 2025, where it first appeared.

Yahoo

14-06-2025

• Yahoo

Oklo Inc (OKLO) – Jumps 30% After New Government Deal

We recently published a list of . In this article, we are going to take a look at where Oklo Inc. (NYSE:OKLO) stands against other best-performing stocks on Wednesday. Oklo Inc. soared by 29.48 percent on Wednesday to finish at $68.03 apiece after it was selected by the US Air Force to deploy its advanced Aurora powerhouse to its military base in Alaska. In a statement, Oklo Inc. (NYSE:OKLO) said the project serves as the Department of the Air Force's (DAF) microreactor pilot to enhance energy resilience and reliability for critical national security infrastructure. Under the terms of the agreement, Oklo Inc. (NYSE:OKLO) will design, construct, own, and operate the power plant at the Eielson Air Force Base in Alaska. 'This Notice of Intent to Award reflects continued confidence in Oklo's ability to deliver clean and secure energy solutions for mission-critical infrastructure,' said Oklo Inc. (NYSE:OKLO) co-founder and CEO Jacob DeWitte. An aerial view of a power plant, symbolizing the company's investments in energy infrastructure sector. 'We are honored to support national defense resilience objectives while demonstrating the value of U.S.-pioneered fast reactor technology,' he added. Overall, OKLO ranks 1st on our list of best-performing stocks on Wednesday. While we acknowledge the potential of OKLO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data